Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9747810 | 0.98 | SLC15A2 (0.46) | SLC15A2ERAP2LNPEPTERTSLC6A5 | |
| SCHEMBL8427583 | 0.98 | SLC15A2 (0.46) | SLC15A2ERAP2LNPEPTERTSLC6A5 | |
| SCHEMBL9748489 | 0.98 | SLC15A2 (0.46) | SLC15A2ERAP2LNPEPTERTSLC6A5 | |
| SCHEMBL31453807 | 0.94 | SLC15A2 (0.50) | SLC15A2ERAP2LNPEPTERTSLC6A5 | |
| SCHEMBL34464922 | 0.91 | SLC15A2 (0.42) | SLC15A2ERAP2LNPEPOPRD1OPRM1 | |
| SCHEMBL4958851 | 0.90 | SLC15A2 (0.50) | SLC15A2ERAP2LNPEPTERTOPRD1 | |
| SCHEMBL4958843 | 0.90 | SLC15A2 (0.50) | SLC15A2ERAP2LNPEPTERTOPRD1 | |
| SCHEMBL8832514 | 0.90 | TERT (0.44) | SLC15A2ERAP2LNPEPTERTOPRD1 | |
| SCHEMBL2823387 | 0.90 | TERT (0.44) | SLC15A2ERAP2LNPEPTERTOPRD1 | |
| SCHEMBL8832652 | 0.89 | TERT (0.44) | SLC15A2ERAP2LNPEPTERTOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | SLC15A2 1915/4885ERAP2 923/4885LNPEP 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.